Product Information
EPLERENONE 25 MG TABLET is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $0.3052 per EA under NDC 59762171002. Its NADAC has been published 667 times since Nov 28, 2013.
FDA first approved this application on Sep 27, 2002. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the eplerenone market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
25 mg/1
Manufacturer
Mylan Pharmaceuticals Inc.NDC
59762171002
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
EPLERENONEApproval Type
Authorized Generic (NDA)
FDA Application
NDA021437FDA Approved
9/27/2002
TE Code
AB
On Market Since
9/27/2002
Pharmacological Classes
Price Statistics
The NADAC for EPLERENONE 25 MG TABLET has been published 667 times since Nov 28, 2013, and over the history we have for it it has declined 82.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.3052 per EA |
|---|---|
| All-time high | $2.2431 (Jul 15, 2015) |
| All-time low | $0.2925 (Nov 20, 2024) |
| 52-week high | $0.4462 |
| 52-week low | $0.3001 |
| Median price | $0.9464 |
| Average price | $1.1726 |
| Largest weekly change | +41.7% (Feb 22, 2023) |
| Weeks tracked | 667 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
-1.3%
6M
-7.2%
1Y
-31.6%
3Y
-51.8%
5Y
-64.8%
All
-82.4%
Last surveyed Sep 2, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
eplerenone market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aldosterone Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of EPLERENONE 25 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for EPLERENONE 25 MG TABLET, manufactured by Mylan Pharmaceuticals Inc., is $0.3052 per EA (NDC 59762171002), effective Sep 2, 2026.
How has the price of EPLERENONE 25 MG TABLET changed over time?
Over the history we have for it, the NADAC for EPLERENONE 25 MG TABLET has declined 82.4%. It has been tracked across 667 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for EPLERENONE 25 MG TABLET?
Since Nov 28, 2013, the NADAC for EPLERENONE 25 MG TABLET has ranged from a low of $0.2925 (Nov 20, 2024) to a high of $2.2431 (Jul 15, 2015), with a median of $0.9464 per EA.
Are there cheaper alternatives to EPLERENONE 25 MG TABLET?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as EPLERENONE 25 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures EPLERENONE 25 MG TABLET?
EPLERENONE 25 MG TABLET (NDC 59762171002) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.